Loading provider…
Loading provider…
Neurology Physician in New York, NY
NPI: 1336110378Primary Practice Location
NEW YORK-PRESBYTERIAN HOSPITAL
5141 Broadway, New York, NY
Primary Employer
Trustees of Columbia University in the City of New York
columbiadoctors.org
HQ Phone
Get MD Andrew's Phone Numberphone_androidMobile
Get MD Andrew's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
NJ State Medical License
2022 - 2027
NY State Medical License
1998 - 2027
CT State Medical License
2023 - 2026
KS State Medical License
2021 - 2025

American Board of Psychiatry and Neurology
Neurology
Memorial Sloan Kettering Cancer Center
Fellowship • Neuro-Oncology
2001 - 2003
New York Presbyterian Hospital (Columbia Campus)
Residency • Neurology
1998 - 2001
Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
Internship • Internal Medicine
1997 - 1998
Vagelos College of Physicians and Surgeons
vagelos.columbia.edu
Medical School
Until 1997
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 12 | 22 |
Authors: Howard Fine, Santosh Kesari, Timothy Cloughesy, Phioanh Nghiemphu, Jan Drappatz, Michael Prados, Susan Chang, Minesh Mehta
Journal: Int J Radiat Oncol Biol Phys
Publication Date: 2010-10-08
Unraveling molecular markers of biologic therapies in glioma.
Authors: Andrew B. Lassman, Lauren E. Abrey
Publication Date: 2006-05
Paroxysmal Apnea and Vasomotor Instability Following Medullary Infarction
Authors: Andrew B. Lassman, Stephan A. Mayer
Publication Date: 2005-08
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, DRUG: Temozolomide, BIOLOGICAL: Ipilimumab, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, PROCEDURE: Contrast-enhanced Magnetic Resonance Imaging, DEVICE: NovoTTF-100A Device
Lead Sponsor: Karyopharm Therapeutics Inc
Intervention / Treatment: DRUG: Selinexor, DRUG: Bevacizumab, DRUG: Carmustine, RADIATION: Standard Fractionated Radiation therapy (RT), DEVICE: TTField, DRUG: Temozolomide (TMZ), DRUG: Lomustine (CCNU)
Lead Sponsor: VBI Vaccines Inc.
Intervention / Treatment: DRUG: Carmustine, DRUG: Lomustine, BIOLOGICAL: VBI-1901